Pattern Bioscience

Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help combat the problem of antibiotic resistance. The pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that can identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps.

Pattern’s Digital CultureTM technology relies on functional endpoints that encompass all possible resistance mechanisms, resulting in a more comprehensive and reliable diagnosis compared to rapid genotypic tests. The platform will deliver more reliable diagnoses days faster than the current standard of care.

Pattern Bioscience headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $3.3B in funding across 60 round(s). With a team of 51-100 employees, Pattern Bioscience is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Pattern Bioscience, raised $28.7M. Discover more about their projects, partnerships, and impact on our platform.